[Prevention of hepatic encephalopathy].
Hepatic encephalopathy (HE) is a frequent complication of cirrhosis which, in addition to producing a great social impact, deteriorates the quality of life of patients and is considered a sign of advanced liver disease and therefore a clinical indication for liver transplant evaluation. Patients who have had episodes of HE have a high risk of recurrence. Thus, after the HE episode resolves, it is recommended: control and prevention of precipitating factors (gastrointestinal bleeding, spontaneous bacterial peritonitis, use of diuretics with caution, avoid nervous system depressant medications), continued administration of non-absorbable disaccharides such as lactulose or lactitol, few or non-absorbable antibiotics such as rifaximin and assess the need for a liver transplant as the presence of a HE episode carries a poor prognosis in cirrhosis.
Unidad de Hepatología, Servicio de Aparato Digestivo, Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España. Electronic address: rmorillas.germanstrias@gencat.cat.
Rosa M
RM
Morillas
Unidad de Hepatología, Servicio de Aparato Digestivo, Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España.
Marga
M
Sala
Unidad de Hepatología, Servicio de Aparato Digestivo, Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España.
Ramon
R
Planas
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D002492:Central Nervous System Depressants / Q000009:adverse effects; D000075202:Contraindications; D004232:Diuretics / Q000009:adverse effects; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006501:Hepatic Encephalopathy / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D022124:Hyperammonemia / Q000209:etiology / Q000517:prevention & control; D007408:Intestinal Absorption; D007792:Lactulose / Q000008:administration & dosage / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation; D015201:Meta-Analysis as Topic; D010538:Peritonitis / Q000150:complications; D011170:Portasystemic Shunt, Surgical / Q000009:adverse effects; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D012008:Recurrence; D012294:Rifamycins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000078262:Rifaximin; D012307:Risk Factors; D013402:Sugar Alcohols / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002492:Central Nervous System Depressants; D004232:Diuretics; D012294:Rifamycins; D013402:Sugar Alcohols; D007792:Lactulose; C014635:lactitol; D000078262:Rifaximin
Cirrosis descompensada; Decompensated cirrhosis; Encefalopatía hepática; Hepatic encephalopathy; Prevención; Prevention